Dr Susan Galbraith

Susan Galbraith trained as a Clinical Oncologist in the United Kingdom. She studied Medicine at Manchester and Cambridge Universities. She was admitted to Membership of the Royal College of Physicians in 1992, and then trained in Clinical Oncology in London. She gained Fellowship of the Royal College of Radiologists in 1997. She then completed a PhD at the University of London involving translational work on a vascular-targeting agent.

Susan joined the Clinical Discovery Oncology group at Bristol-Myers Squibb in 2001. Susan was closely involved in the in-licensing of ipilimumab from Medarex, elotuzumab from PDL, the acquisitions of Adnexus and Medarex and research collaborations with Exelixis. She held increasing levels of responsibility becoming VP for Oncology and Immunology Early Development, and then latterly taking on responsibility for the Clinical Biomarker team.

Susan joined AZ in September 2010, as Head of the Oncology iMed responsible for Oncology Discovery and Early Development to Proof of Concept